Laurion Capital Management’s Acceleron Pharma XLRN Stock Holding History

Laurion Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-14,617	Closed	-$1.39M	–	1252
2020 Q2	$1.39M	Buy	+14,617	New	+$1.41M	0.02%	357
2020 Q1	–	Sell	-13,127	Closed	-$696K	–	1201
2019 Q4	$696K	Buy	13,127 +6,127	+88%	+$279K	0.01%	635
2019 Q3	$277K	Sell	7,000 -17,219	-71%	-$747K	﹤0.01%	880
2019 Q2	$995K	Buy	+24,219	New	+$1M	0.01%	570
2017 Q4	–	Sell	-142,630	Closed	-$5.32M	–	1954
2017 Q3	$5.32M	Buy	+142,630	New	+$4.95M	0.02%	491
2017 Q1	–	Sell	-202,738	Closed	-$5.17M	–	1643
2016 Q4	$5.17M	Sell	202,738 -487,262	-71%	-$15.4M	0.05%	342
2016 Q3	$25M	Buy	+690,000	New	+$22.9M	0.23%	96

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Laurion Capital Management's XLRN Position: Q3 2020 in Review

Laurion Capital Management sold out of Acceleron Pharma (XLRN) in Q3 2020, closing a stake of 14,617 shares — an estimated $1.39M sold.

Laurion Capital Management first reported a position in XLRN in Q3 2016 and held it in 7 quarters. The position peaked at $25M in Q3 2016. 238 funds tracked by Wall St. Rank hold XLRN as of Q3 2020.

Laurion Capital Management reported no remaining Acceleron Pharma position as of Q3 2020 after selling out during the quarter.
Laurion Capital Management sold 14,617 Acceleron Pharma shares in Q3 2020, an estimated $1.39M.
Laurion Capital Management first reported a position in Acceleron Pharma in Q3 2016 and held it in 7 quarters.
Laurion Capital Management's Acceleron Pharma position peaked at $25M in Q3 2016.
238 funds tracked by Wall St. Rank held Acceleron Pharma as of Q3 2020.

Based on Laurion Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.